- Home
- BBIO vs H Comparison
BBIO vs H Comparison
Compare BBIO & H Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- H
- Stock Information
- Founded
- BBIO 2015
- H 1957
- Country
- BBIO United States
- H United States
- Employees
- BBIO N/A
- H N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- H Hotels/Resorts
- Sector
- BBIO Health Care
- H Consumer Discretionary
- Exchange
- BBIO Nasdaq
- H Nasdaq
- Market Cap
- BBIO 12.5B
- H 13.9B
- IPO Year
- BBIO 2019
- H 2009
- Fundamental
- Price
- BBIO $71.90
- H $167.26
- Analyst Decision
- BBIO Strong Buy
- H Buy
- Analyst Count
- BBIO 19
- H 16
- Target Price
- BBIO $74.79
- H $159.56
- AVG Volume (30 Days)
- BBIO 2.4M
- H 1.1M
- Earning Date
- BBIO 10-29-2025
- H 11-06-2025
- Dividend Yield
- BBIO N/A
- H 0.36%
- EPS Growth
- BBIO N/A
- H N/A
- EPS
- BBIO N/A
- H N/A
- Revenue
- BBIO $353,780,000.00
- H $3,339,000,000.00
- Revenue This Year
- BBIO $123.32
- H $121.54
- Revenue Next Year
- BBIO $73.46
- H $4.88
- P/E Ratio
- BBIO N/A
- H N/A
- Revenue Growth
- BBIO 62.46
- H N/A
- 52 Week Low
- BBIO $25.34
- H $102.43
- 52 Week High
- BBIO $72.26
- H $168.20
- Technical
- Relative Strength Index (RSI)
- BBIO 71.58
- H 72.14
- Support Level
- BBIO $64.41
- H $147.10
- Resistance Level
- BBIO $67.71
- H $158.84
- Average True Range (ATR)
- BBIO 2.80
- H 4.71
- MACD
- BBIO 0.35
- H 1.73
- Stochastic Oscillator
- BBIO 95.73
- H 98.51
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About H Hyatt Hotels Corporation
Hyatt is an operator of owned (3% of total rooms) and managed and franchised (97%) properties across about 30 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 63% Americas, 15% rest of world, and 22% Asia-Pacific.